| Cat. No. |
Product Name |
CAS No. |
Information |
| PC-35254 |
GLP-26
|
2133017-36-2 |
GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM; GLP26 is a potent inhibitor of cccDNA formation and HBeAg production against the mutant core T109I, demonstrates synergistic activity with ETV in the HepAD38 system, reducing HBV DNA replication.
|
| PC-35216 |
JNJ-632
|
1572510-42-9 |
JNJ-632 (JNJ632) is a novel potent HVV capsid assembly modulator and HBV replication inhibitor with EC50 of 100-200 nM for genotypes A-D; does not show cytotoxicity for HepG2 cells (CC50>100 uM); dose-dependently reduces intracellular HBV RNA levels as well as HBe/cAg and HBsAg levels in the cell culture supernatant.
|
| PC-63327 |
AT-130
|
211364-06-6 |
AT-130 is a potent inhibitor of HBV capsid assembly, inhibits wild-type HBV replication with IC50 of 2.4 uM; inhibits replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro with same sensitivity (rtL180M, rtM204I, and rtL180M + rtM204V); blocks HBV replication at the level of viral RNA packaging, interferes with capsid morphogenesis, shows activity against the main lamivudine- and adefovir-resistant mutants.
|
| PC-63323 |
AB-423
|
1572510-80-5 |
AB-423 is a novel potent, class II HBV capsid inhibitor that shows potent inhibition of HBV replication with EC50 of 0.08-0.27 uM, with no significant cytotoxicity (CC50>10 uM); inhibits HBV genotypes A through D and nucleos/tide-resistant variants, causes capsid particles devoid of encapsidated pgRNA and rcDNA in treated HepDES19 cells, prevents the conversion of encapsidated rcDNA to cccDNA presumably by interfering with the capsid uncoating process; dose-dependently reduces serum HBV DNA levels in mouse model of HBV model, shows synergistic antiviral activity combined with entecavir (ETV).
HBV Infection
Phase 1 Clinical
|
| PC-35873 |
NVR 3-778
|
1445790-55-5 |
NVR 3-778 (NVR3-778, NVR 3778) is a small molecule inhibitor of HBV replication that targets the viral core protein, a first-in-class capsid assembly modulator; inhibits the generation of infectious HBV DNA containing virus particles with EC50 of 0.40 uM in HepG2.2.15 cells; NVR 3-778 inhibits pgRNA encapsidation, viral replication and the production of HBV DNA- and HBV RNA-containing particles, also inhibits de novo infection and viral replication in primary human hepatocytes with EC50 of 0.81 uM against HBV DNA and 3.7-4.8 uM against the production of HBV antigens and intracellular HBV RNA; demonstrates favorable pharmacokinetics and safety in animal species. HBV Infection Phase 1 Clinical |
| PC-35638 |
NTCP binder peptide WD1
|
|
NTCP binder peptide WD1 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=15 nM), reduces HBs antigen levels in culture supernatants; also inhibits cellular entry by the related hepatitis D virus (HDV), and is active against diverse strains of HBV (including clinically relevant nucleos(t)ide analog-resistant and vaccine escaping strains); exhibitsno inhibition of NTCP-mediated bile acid uptake in contrast to other NTCP-binding HBV entry inhibitors. |
| PC-35637 |
NTCP binder peptide WL4
|
|
NTCP binder peptide WL4 is a macrocyclic peptide, pan-genotypic inhibitor of HBV cellular entry via targeting the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP, Kd=42 nM), reduces HBs antigen levels in culture supernatants with IC50 of 0.66 uM; also inhibits cellular entry by the related hepatitis D virus (HDV), and is active against diverse strains of HBV (including clinically relevant nucleos(t)ide analog-resistant and vaccine escaping strains); exhibitsno inhibition of NTCP-mediated bile acid uptake in contrast to other NTCP-binding HBV entry inhibitors. |
